Clin Hypertens.
2023;29(1):11. 10.1186/s40885-023-00234-9.
The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension
- Affiliations
-
- 1Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea
- 2Department of Internal Medicine, Wonkwang University Sanbon Hospital, Wonkwang University School of Medicine, Gunpo, Republic of Korea
- 3Department of Internal Medi‑ cine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
- 4Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
- 5Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
- 6Department of Inter‑ nal Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea
- 7Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
- 8Department of Internal Medicine, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Republic of Korea
- 9Department of Neurology, Uijeongbu Eulji Medical Center, Eulji University, Uijeongbu, Republic of Korea.
- 10Department of Internal Medicine, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- 11Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- 12Department of Internal Medicine, Hanyang University Medical Center, Hanyang Univer‑ sity College of Medicine, Seoul, Republic of Korea.
- 13Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University School of Medicine, Seoul, Republic of Korea.
- KMID: 2539441
- DOI: http://doi.org/10.1186/s40885-023-00234-9
Abstract
- Hypertension is the leading cause of death in human being, which shows high prevalence and associated complica‑ tions that increase the mortality and morbidity. Controlling blood pressure (BP) is very important because it is well known that lowering high BP effectively improves patients’ prognosis. This review aims to provide a focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension. The importance of ambula‑ tory BP and home BP monitoring was further emphasized not only for the diagnosis but also for treatment target. By adopting corresponding BPs, the updated guideline recommended out-of-office BP targets for both standard and intensive treatment. Based on the consensus on corresponding BPs and Systolic Blood Pressure Intervention Trial (SPRINT) revisit, the updated guidelines recommended target BP in high-risk patients below 130/80 mmHg and it applies to hypertensive patients with three or more additional cardiovascular risk factors, one or more risk factors with diabetes, or hypertensive patients with subclinical organ damages, coronary or vascular diseases, heart failure, chronic kidney disease with proteinuria, and cerebral lacunar infarction. Cerebral infarction and chronic kidney disease are also high-risk factors for cardiovascular disease. However, due to lack of evidence, the target BP was generally determined at < 140/90 mmHg in patients with those conditions as well as in the elderly. Updated contents regarding the man‑ agement of hypertension in special situations are also discussed.
